In this four-minute video, members of ViewRay's Scientific and Clinical Advisory Boards talk about the need for—and the potential of—the MRIdian system. "We believe this could be a paradigm changer in our field," says Sasa Mutic, PhD, professor of radiation oncology at Washington University.
Daniel Moore, Chairman
Mr. Moore has served as Chairman of LivaNova's board of directors since 2015. Previously he served as a member of the board and chief executive officer of Cyberonics from 2007. Mr. Moore joined Cyberonics from Boston Scientific, where he held positions in sales, marketing and senior management in the U.S. and in Europe. His last position at Boston Scientific was president, International Distributor Management. Prior to that role, he held the position of president, Inter-Continental, a business unit of Boston Scientific. Mr. Moore earned a Bachelor of Arts from Harvard University, and a Masters of Business Administration with High Honors from Boston University.
David Bonita M.D.
David Bonita, M.D. has served as a member of our board of directors since January 2008. Dr. Bonita has served as a Private Equity Partner at OrbiMed Advisors LLC, or OrbiMed, since June 2013. Dr. Bonita joined OrbiMed in June 2004 as a Private Equity Senior Associate, and was promoted to Private Equity Principal in December 2007. Prior to OrbiMed, he was a corporate finance analyst in the healthcare investment banking group of Morgan Stanley & Co. from February 1998 to July 1999, and a corporate finance analyst in the healthcare investment banking group of UBS AG from August 1997 to February 1998. Dr. Bonita has also served on the board of directors of Loxo Oncology, Inc. since October 2013, as well as on the boards of directors of several private companies. Dr. Bonita holds an A.B. in Biological Sciences from Harvard College and an M.D. and M.B.A. from Columbia University in the City of New York. We believe Dr. Bonita is qualified to serve on our board of directors due to his extensive investment experience in the healthcare industry.
Caley Castelein M.D.
Caley Castelein, M.D. has served as a member of our board of directors since January 2008. Dr. Castelein has served as a Managing Director of Kearny Venture Partners, L.P. since September 2006. Prior to that, Dr. Castelein served as a Managing Director at Thomas Weisel Partners, which was acquired by Stifel, Nicolaus & Company, Incorporated in July 2010, from March 2003 to September 2006. Dr. Castelein has served on the boards of directors of several private companies. Dr. Castelein holds an A.B. in Biological Sciences from Harvard College and an M.D. from the University of California, San Francisco. We believe Dr. Castelein is qualified to serve on our board of directors based on his extensive investment experience in the healthcare industry.
James F. Dempsey Ph.D.
James F. Dempsey, Ph.D. has served as our Chief Scientific Officer since founding ViewRay in March 2004. Dr. Dempsey has been a member of the board of directors since January 2008. Dr. Dempsey brings more than 17 years of experience in the field of radiotherapy medical physics to ViewRay. He previously served as a faculty member in the University of Florida Department of Radiation Oncology, as Assistant Professor from July 2001 to July 2007 and Associate Professor from July 2007 to January 2008. Dr. Dempsey holds a B.S. in Radiochemistry from San Jose State University and a Ph.D. in Nuclear Chemistry from Washington University in St. Louis. We believe Dr. Dempsey is qualified to serve on our board of directors based on his in-depth knowledge of our product, business and industry, as well as his expertise in nuclear chemistry and physics and medical physics.
Mark S. Gold M.D.
Mark S. Gold, M.D. has served as a member of our board of directors since our founding in March 2004. Dr. Gold was a Professor, Distinguished Professor and Chairman of Psychiatry at the University of Florida from 1990 until his retirement in June 2014. Dr. Gold has worked for over 40 years in basic science and clinical research, translating research into clinical practice. He has been a consultant and senior advisor to banks and private equity and venture capital firms on medical devices, pharmaceuticals and health care services throughout his career. He was a Founding Director of the Somerset Valley Bank and Somerset Valley Financial from 1991 to 1999. Dr. Gold has served on the board of directors of Axogen, Inc. (formerly LecTec Corporation) since September 2011. Dr. Gold is currently the Chairman of RiverMend Health. We believe Dr. Gold is qualified to serve on our board of directors because of his academic expertise and his extensive research experience across medical specialties and institutions.
Mr. Huennekens is currently chairman, president and chief executive officer of Verb Surgical, which he joined in August 2015. Previously, Mr. Huennekens served as president and chief executive officer of Volcano Corporation from its start-up in 2002, through its IPO in 2006, and to its eventual sale to Royal Philips in 2015. Prior to his work at Volcano, Mr. Huennekens served as president and chief executive officer of Digirad Corporation, a diagnostic imaging solutions provider. Mr. Huennekens is a board member and past chairman of the Medical Device Manufacturer's Association (MDMA). He graduated magna cum laude with a Bachelor of Science in Business Administration from the University of Southern California in 1986 and earned his Masters of Business Administration from the Harvard Business School in 1991.
Dr. Henry A. McKinnell Jr.
Dr. McKinnell retired as Chairman and CEO of Pfizer Inc. in 2006. His 35 years with the company included the positions of President of Pfizer Asia, President of Pfizer's medical devices group, President of Pfizer Pharmaceuticals Group, and Chief Financial Officer.
Dr. McKinnell currently serves as the Chairman of the Board of Moody's Corporation and Chairman of the Board of the Accordia Global Health Foundation. His previous directorships include ExxonMobil Corporation, John Wiley & Sons, Optimer Pharmaceuticals, Inc., Emmaus Life Sciences, Inc., and Angiotech Pharmaceuticals, Inc.
Previously, Dr McKinnell chaired the Business Roundtable, an association of Chief Executive Officers leading U.S. companies with $7 trillion in annual revenues, the Health Industry Manufacturers Association (now known as AdvaMed), the Pharmaceutical Research and Manufacturers of America, the Food and Drug Law Institute, Stanford University Graduate School of Business Advisory Council, and the Connecticut Science Center. Dr. McKinnell also served as Vice Chairman of the World Economic Forum.
Dr. McKinnell has received numerous awards, including the Grand Cordon of the Order of the Rising Sun, Japan's highest award other than to members of the Imperial Family and heads of state.
Aditya Puri has served as a member of our board of directors since February 2015. Mr. Puri has served as an Investments Director at Xeraya Capital, which is responsible for life sciences investments for Khazanah Nasional Berhad, since October 2012. Previously, he was a Director in Khazanah Nasional’s Life Sciences unit since November 2011, which was responsible for Khazanah’s life sciences investments. Prior to that, Mr. Puri consulted part time in the greater Boston area for various healthcare and cleantech startups affiliated with Harvard University and Massachusetts Institute of Technology, or MIT, from 2009 to 2011. Mr. Puri also served as Managing Director of global development at Salary.com from July 2007 to April 2008. Mr. Puri was at the Yankee Group, a global technology research and consulting company, from September 2000 to March 2007, finishing his tenure as a Vice-President and member of the leadership team. Between March 1997 and April 2000, he was at Boston Scientific, a Fortune 500 medical device manufacturer. Mr. Puri serves on several boards of directors of private companies in the investment and healthcare fields. Mr. Puri has a B.S. from the University of Southern Maine and received an M.B.A. from the MIT Sloan School of Management. We believe Mr. Puri is qualified to serve on our board of directors because of his extensive experience in life sciences investment and growth.
Chris A. Raanes
Chris A. Raanes has served as our President and Chief Executive Officer and as a member of the board of directors since February 2013. Mr. Raanes brings over 15 years of experience in the private and public medical device field. As our President and Chief Executive Officer, Mr. Raanes has supported our growth and strategic initiatives, including our worldwide commercial expansion of MRIdian®. Previously, Mr. Raanes was Executive Vice President from July 2011 to November 2012 and Chief Operating Officer and Senior Vice President from September 2002 to July 2011 at Accuray Incorporated, a medical device company. He also served as Vice President and General Manager, Digital Imaging at PerkinElmer Inc., a healthcare company, from December 1999 to March 2002. Mr. Raanes holds a B.S. and an M.S. in Electrical Engineering from the Massachusetts Institute of Technology. We believe Mr. Raanes is qualified to serve on our board of directors because of his extensive management experience and his expertise in radiation therapy device commercialization and operations.
Brian K. Roberts
Brian K. Roberts previously served as the Chief Operating and Financial Officer of Avedro, the leader in corneal cross-linking science, which recently completed a $32 million equity financing. Prior to Avedro, Roberts served as CFO for Insulet Corporation. During his time at Insulet, the tubeless insulin pump technology company grew from approximately $30 million to nearly $300 million in revenue, achieved operating profitability, and increased its market capitalization to over $2 billion.
Previously, Roberts served as CFO for Jingle Networks, a leader in mobile voice-ad services that was acquired by Marchex, Inc., and as CFO for Digitas, which was sold for $1.3 billion to Publicis Groupe. He holds a Bachelor of Science in Accounting and Finance from Boston College, is a Certified Public Accountant, and served as an auditor with Ernst & Young LLP.
Theodore T. Wang, Ph.D.
Theodore T. Wang, Ph.D. has served as a member of our board of directors since January 2017. Dr. Wang currently serves as the Chief Investment Officer of Puissance Capital Management, of which he was a founder, since January 2015. Prior to that, Dr. Wang was a Partner of Goldman, Sachs & Co. (“Goldman”), which he joined in 1996 and with which he served in many leadership positions, mostly recently as Co-Head of U.S. Equities Trading and Global Co-Head of One Delta Trading and a member of the Goldman Sachs Risk Committee. Prior to joining Goldman, Dr. Wang co-founded Xeotron Corp., a company specializing in DNA biochips in Texas. Dr. Wang holds a Ph.D. in Physics from the University of Minnesota, an M.B.A. from the University of Texas, Austin, and a B.S. from Fudan University, China. We believe Dr. Wang is qualified to serve on our board of directors because of his prior investment and leadership experience in the life science industry.
John Bayouth, PhD, University of Wisconsin, Madison
Jeffrey Bradley, MD, Washington University, St. Louis, Missouri
Carlos A. Perez, MD, Washington University, St. Louis, Missouri
Ben Slotman, MD, VU University Medical Center, Amsterdam
Michael Steinberg, MD, University of California, Los Angeles
Vincenzo Valentini, MD, Universita Cattolica S. Cuore Roma
Hong-Gyun Wu, MD, Seoul National University Hospital, Seoul, South Korea